Next Science (ASX:NXS) Debt-to-EBITDA : -0.07 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Next Science Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Next Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.41 Mil. Next Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$1.03 Mil. Next Science's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-19.78 Mil. Next Science's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Next Science's Debt-to-EBITDA or its related term are showing as below:

ASX:NXS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.1 Med: -0.04 Max: -0.02
Current: -0.07

During the past 6 years, the highest Debt-to-EBITDA Ratio of Next Science was -0.02. The lowest was -0.10. And the median was -0.04.

ASX:NXS's Debt-to-EBITDA is ranked worse than
100% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs ASX:NXS: -0.07

Next Science Debt-to-EBITDA Historical Data

The historical data trend for Next Science's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Debt-to-EBITDA Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.04

-0.02

-0.03

-0.10

-0.07

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial					-0.02	-0.11	-0.09	-0.48	-0.07

Competitive Comparison of Next Science's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Next Science's Debt-to-EBITDA falls into.

Next Science Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Next Science's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.411	+	1.026)	/	-21.546
	=	-0.07

Next Science's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.411	+	1.026)	/	-19.778
	=	-0.07

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Next Science (ASX:NXS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Next Science Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Next Science's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (ASX:NXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines